Member Info for DeBull

Very good OSD

PYC = P:rofits Yearning Cometh.

Avocet, its never had a profit, are you now intimating that a profit is now on the way?

Is this in relation to NM26 or ND081?

Interesting quote from PS "We're delighted to be deepening our existing relationship with Numab Therapeutics through this new project. Applying our MIDD expertise to support early clinical development aligns perfectly with our mission to help clients make smarter, faster decisions that can help de-risk development and improve outcomes. We are also pleased to be supporting the development of a therapy targeting inflammation, demonstrating our service expansion beyond oncology."

Numab is developing multiple proprietary inflammation programs utilizing our versatile, multi-specific MATCH™ platform. We are combining antagonism of multiple disease-driving pathways to create innovative, multi-functional drug candidates. With these rationally designed drug candidates we seek to exceed the reaches of current standard of care medication in inflammatory diseases to provide much needed improvement in the quality of life for patients.

https://numab.com/pipeline/

Dr Peter Sargent, CEO of Physiomics, commented:

"I am thrilled that the changes we've made here at Physiomics are starting to have a positive effect on the Company's performance. Not only will we exceed expectations for FY25, but we've started FY26 with record levels of contracted revenue yet to be recognised and are generating significant momentum across our key growth initiatives."

Https://www.londonstockexchange.com/news-article/PYC/trading-update/17131795

PS was at https://www.linkedin.com/company/smallcap/ a few weeks ago.

Even after a decent RNS and several recently, the SP is stagnant at best. The selling continues to. People selling can not be making any money at all? Roll on Doseme.

Non oncology project.

Existing client.

£98k over 18 months equates to £5.4k a month.

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract award with an existing client.

In this new project, Physiomics will apply PK/PD modelling and simulation expertise to support preclinical-to-clinical translation for one of the client's lead candidates and inform selection of human dosing schemes for a First in Human clinical trial.

This contract, which supports the development of a non-oncology therapeutic, highlights the value of Physiomics' integrated modelling and simulation approach across the drug development lifecycle - from early discovery through translational planning and into clinical development. The contract is valued at £98,600 and will be delivered over the next 18 months.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are delighted to continue partnering with this client and announce this follow on work with their team. Working with them from early discovery through to clinical planning enables us to add deeper insights into their experimental and clinical trial design, helping them accelerate this promising drug development programme."

Https://www.londonstockexchange.com/news-article/PYC/contract-award/17111709?showDisclaimer=true

2.6m sell, and the SP does not flinch. Dropped at the end of the day, over 3 hours after the large sell.

Becoming ever more active....... https://www.linkedin.com/posts/beyond-blood-diagnostics_london-biotechnology-show-activity-7339231929453465600-N0lO?utm_source=share&utm_medium=member_desktop&rcm=ACoAADD2_GEBbBQq8Myl625L0_Oaho7nn5p-oxI

Https://www.londonstockexchange.com/news-article/PYC/new-head-of-biometrics-and-two-contracts-awarded/17086478?showDisclaimer=true

Before the last spike to .60, it was sat at .405, over the recent sessions it got down to .425 before buyers and Trouts 3M purchase kicked in. As alluded to, various news is due. Lets hope now that .425 is the bottom. Roll on Docetaxel.

Another 10%+ rise. Good.

over 100m shares traded in last 2 days, thats a third of the 300m in issue. Good

MS, if i read your comments right, we need to hold above .55 for certain things to come into play, is that correct?

Doseme news another day closer.

Probably get lambasted for my observations, but there you go.

In the last 2 positive RNS's re extension and contract, the SP fell during the days of those announcements? Yesterday is took off, before ending over 10%. Even with the news flow very soon, the excellent contributions of Trench and King, i feel today, like the last few times "could" have all the hallmarks of a P&D. The way all those large trade rolled in first thing, to set the SP on its way, i would guess that some of those large trades could be matched for the drop back to 10%+. Just all looked a bit suss to me.

The way the market reacted to the previous 2 good news days was negative, yet yesterday it sprang into life on nothing. We have seen in the last few months where the SP has taken off, only to come back to near where it started. Hope i am, wrong, and i hope the SP continues to improve, but its just the way i see it.

Https://doseme-rx.com/why-dosemerx/drug-packages

Docetaxel is still a "gold" colour for development. All eyes on it turning "green" and Validation, that is where things start to get interesting.

Todays RNS says this which is also interesting "The project builds upon the contract award announced on 13 June 2024, where the Company's proprietary Virtual Tumour platform has been used to model the client's targeted oncology agents in combination with other modalities so to help inform dose and scheduling decisions." "other modalities" ?? Also used in the 13/96/24 RNS.

The You tube video was uploaded in May 2025. According to way back machine (internet archive) the https://www.beyondblood.co/copy-of-technology-1 was modified in March 2025, however there appears to be no visible modification between a snapshot in March 2025 and Jan 2025. Their whole site is saying copyright 2024. As posted by Ralph i believe, BB are recently hiring.

We know that some PYC tech is integrated with Doseme & is available to a few selected clients on a research basis. Docetaxel is still in its "Development" stage, and has been for several months. Next stage as mentioned before is "Validation"